Suppr超能文献

血管紧张素转换酶 2(ACE2)受体和 SARS-CoV-2:潜在的治疗靶点。

Angiotensin-converting enzyme 2 (ACE2) receptor and SARS-CoV-2: Potential therapeutic targeting.

机构信息

Systematic Review and Meta-analysis Expert Group (SRMEG), Universal Scientific Education and Research Network (USERN), Tehran, Iran; School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.

Systematic Review and Meta-analysis Expert Group (SRMEG), Universal Scientific Education and Research Network (USERN), Tehran, Iran; Students' Scientific Research Center (SSRC), Tehran University of Medical Sciences, Tehran, Iran.

出版信息

Eur J Pharmacol. 2020 Oct 5;884:173455. doi: 10.1016/j.ejphar.2020.173455. Epub 2020 Jul 31.

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a beta coronavirus that uses the human angiotensin-converting enzyme 2 (ACE2) receptor as a point of entry. The present review discusses the origin and structure of the virus and its mechanism of cell entry followed by the therapeutic potentials of strategies directed towards SARS-CoV2-ACE2 binding, the renin-angiotensin system, and the kinin-kallikrein system. SARS-CoV2-ACE2 binding-directed approaches mainly consist of targeting receptor binding domain, ACE2 blockers, soluble ACE2, and host protease inhibitors. In conclusion, blocking or manipulating the SARS-CoV2-ACE2 binding interface perhaps offers the best tactic against the virus that should be treated as a fundamental subject of future research.

摘要

严重急性呼吸综合征冠状病毒 2(SARS-CoV-2)是一种β冠状病毒,它使用人类血管紧张素转换酶 2(ACE2)作为进入点。本综述讨论了病毒的起源和结构及其细胞进入机制,然后讨论了针对 SARS-CoV2-ACE2 结合、肾素-血管紧张素系统和激肽-激肽释放酶系统的治疗潜力。SARS-CoV2-ACE2 结合靶向方法主要包括针对受体结合域、ACE2 阻滞剂、可溶性 ACE2 和宿主蛋白酶抑制剂。总之,阻断或操纵 SARS-CoV2-ACE2 结合界面可能是对抗该病毒的最佳策略,应将其视为未来研究的基础课题。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5d9c/7834210/af39575fa449/gr1_lrg.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验